Heart Disease News and Research

Latest Heart Disease News and Research

Adequate calcium intake maintains optimum bone mass

A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.

31 Jul 2010

Research Roundup:COBRA subsidies; Children's insurance and dental coverage; Adopting health IT; Race and heart treatments

Archives of Internal Medicine: Racial Differences In Admissions To High-Quality Hospitals For Coronary Heart Disease - "Racial disparities in the management of coronary heart disease (CHD) are widely documented, yet the reasons behind persistent gaps in quality of care are not fully understood," write the authors, who examined "Medicare patients with acute myocardial infarction and coronary artery bypass grafting (CABG) admitted during 2002 through 2005 to hospitals located in markets with top-ranked cardiac hospitals, as ascertained from the US News and World Report 'America's Best Hospitals' annual rankings."

31 Jul 2010

FDA clears ZOLL's new Propaq MD Monitor/Defibrillator

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market and begin distribution of the new Propaq® MD Monitor/Defibrillator that was developed specifically to meet the special needs of military customers and air medical operations worldwide. Development of this product was a joint undertaking between the Department of Defense and a cooperative arrangement between Welch Allyn and ZOLL.

30 Jul 2010

USIBC applauds Abbott for 100 years of improving healthcare in India

Today the U.S.-India Business Council (USIBC) saluted Abbott Laboratories for 100 years of improving healthcare in India. In 1910, Abbott was one of the first multinationals to establish operations in India. Over the past century, Abbott has been dedicated to connecting Indian patients with access to quality medication and patient care, enhancing the quality of life for its customers.

30 Jul 2010

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

Endo Pharmaceuticals today reported financial results for the second quarter 2010. Total revenues during the second quarter of 2010 increased 6 percent to $396.5 million, compared with $373.1 million in the same quarter of 2009. Net income for the three months ended June 30, 2010 was $51.5 million, compared with $30.0 million in the comparable 2009 period.

30 Jul 2010

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Geron Corporation announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron's Investigational New Drug (IND) application has been lifted and the company's Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed.

30 Jul 2010

Higher case volume associated with better outcomes of cardiac surgery: Study

A new analysis led by researchers at UCSF shows that avoiding lowest-volume hospitals and maximizing adherence to quality care processes are both effective approaches to reducing costs associated with coronary bypass surgery.

30 Jul 2010

$Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released$

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE (bortezomib) in patients with relapsed/refractory mantle cell lymphoma. The data, derived from an analysis of archived tumor samples, tested pre-specified biomarkers for their association with time to progression and response to treatment with VELCADE in patients with relapsed MCL.

30 Jul 2010

Volcano second-quarter revenues increase 36% to record $73.5 million

Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that revenues in the second quarter of 2010 increased 36 percent versus revenues in the second quarter of 2009.

30 Jul 2010

VAPAHCS acquires 15 Zargis Cardioscan systems

Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that the VA Palo Alto Health Care System, a northern California based hospital group that is part of The Department of Veterans Affairs nationwide network of hospitals, recently purchased 15 Zargis Cardioscan systems.

30 Jul 2010

HSFC supports SWG's report on reducing sodium levels

The Heart and Stroke Foundation of Canada strongly supports the report released today by the Sodium Working Group.

30 Jul 2010

Governor Rendell announces $2.5M investment to help boost higher education, health care industries

Colleges, universities, academic medical institutions and research institutions across Pennsylvania will be better able to recruit top faculty researchers and get products to the marketplace faster with a new $2.5 million investment announced today by Governor Edward G. Rendell.

30 Jul 2010

Resveratrol suppresses inflammation and free radicals: Study

Resveratrol, a popular plant extract shown to prolong life in yeast and lower animals due to its anti-inflammatory and antioxidant properties, appears also to suppress inflammation in humans, based on results from the first prospective human trial of the extract conducted by University at Buffalo endocrinologists.

30 Jul 2010

Genetics research team discovers new recurrent translocations

A genetics research team based at The Children's Hospital of Philadelphia continues to discover recurrent translocations—places in which two chromosomes exchange pieces of themselves. As many as 1 in 600 persons carry balanced chromosome translocations, which involve no loss or gain of DNA. Most such people appear healthy, but may have a child with abnormal chromosome composition and disabilities resulting from disrupted, extra or missing copies of genes.

30 Jul 2010

NewCardio enters new line of credit with existing shareholders

NewCardio, Inc., a cardiac diagnostic technology provider, today announced that it has entered into a new line of credit with three of its existing shareholders, one of which is represented on the Board of Directors, to strengthen its financial position. This will allow the company further time to fully commercialize its lead solution, QTinno™.

30 Jul 2010

VitaPath Genetics launches VitaTrack Folate Tracker

VitaPath Genetics, the Spina Bifida Association and the National Council on Folic Acid today announced the launch of the free iPhone application—the VitaTrack Folate Tracker— which allows women to track their daily intake of folate and folic acid. Maintaining an adequate level of folic acid prior to and during pregnancy can reduce the risk of serious birth defects like Spina Bifida by up to 70%. Studies show that folic acid may also help prevent congenital heart disease, pre-term labor, and cleft lip and palate.

30 Jul 2010

Bio-Path commences dosing in Liposomal Grb-2 Phase I cancer study

Bio-Path Holdings, Inc.,, a biotechnology company with drug development operations in Houston, Texas, announced today that the first patient has been dosed in a Phase I study of its cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), in patients with Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) or Myelodysplastic Syndrome (MDS).

30 Jul 2010

CryoLife second-quarter revenues increase 4% to record $29.3 million

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the second quarter of 2010. Revenues for the second quarter increased 4 percent to a second quarter record of $29.3 million compared to $28.2 million for the second quarter of 2009. Net income for the second quarter of 2010 was $2.9 million, or $0.10 per basic and fully diluted common share, compared to $2.5 million, or $0.09 per basic and fully diluted common share, for the second quarter of 2009.

30 Jul 2010

Study on link between SNP and concentrations of serum creatinine

Scientists at deCODE genetics and colleagues at Radboud University in the Netherlands today describe how the impact of a single letter variation in the sequence of the human genome conferring risk of kidney disease varies with age and with the onset of other diseases. The study provides independent confirmation of the association made in an earlier study between a version of the the SNP, located on chromosome 16p12, and risk of chronic kidney disease. It also confirmed the link between the SNP and concentrations of serum creatinine, a key indicator of kidney function.

30 Jul 2010

AIDS 2010 follow-up coverage: Global HIV/AIDS funding; HIV/AIDS studies, releases

Media outlets continued to reflect on news from the International AIDS Conference-AIDS 2010, which attracted over 19,000 participants from 197 countries to Vienna last week, according to the conference blog.

30 Jul 2010